Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …

Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-
negative breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC). This article …

Around 40–50% of all triple-negative breast cancer (TNBC) patients achieve a pathological
complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). The …

Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …

PURPOSE The achievement of pathologic complete response (pCR) is strongly prognostic
for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer …

Abstract On July 26, 2021, the FDA granted approval to pembrolizumab in combination with
chemotherapy for neoadjuvant treatment and then continued as a single agent for adjuvant …

Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast
cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early …

Importance The pathologic complete response (pCR) is supported by regulatory agencies
as a surrogate end point for long-term patients' clinical outcomes in the accelerated approval …